Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

Regulators in the U.S. and the European Union agreed to review Biogen’s applications for approval of a higher dose Spinraza ...

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...

Plc climbed 4% Friday following reports from Bloomberg News it is reviewing a possible sale of its drinks portfolio, including Guinness beer and a partnership with LVMH (EPA:LVMH) in the Champagne and ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

However, the sector faces another kind of risk, with a new administration in charge in Washington.

AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based ...

BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.